Cervomed Inc (CRVO)

$16.25

-0.33

(-1.99%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $16.03
    $17.25
    $16.25
    downward going graph

    1.35%

    Downside

    Day's Volatility :7.07%

    Upside

    5.8%

    downward going graph
  • $4.28
    $26.38
    $16.25
    downward going graph

    73.66%

    Downside

    52 Weeks Volatility :83.78%

    Upside

    38.4%

    downward going graph

Returns

PeriodCervomed IncIndex (Russel 2000)
3 Months
-31.98%
0.0%
6 Months
80.55%
0.0%
1 Year
114.1%
0.0%
3 Years
114.1%
-20.8%

Highlights

Market Capitalization
165.1M
Book Value
$0.87
Earnings Per Share (EPS)
-0.2
Wall Street Target Price
55.0
Profit Margin
-51.36%
Operating Margin TTM
-110.55%
Return On Assets TTM
-90.48%
Return On Equity TTM
0.0%
Revenue TTM
8.1M
Revenue Per Share TTM
1.98
Quarterly Revenue Growth YOY
66.7%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.6
EPS Estimate Next Year
-2.28
EPS Estimate Current Quarter
-0.95
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Cervomed Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 238.46%

Current $16.25
Target $55.00

Technicals Summary

Sell

Neutral

Buy

Cervomed Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cervomed Inc
Cervomed Inc
-18.42%
80.55%
114.1%
114.1%
114.1%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cervomed Inc
Cervomed Inc
NA
NA
NA
-1.6
0.0
-0.9
NA
0.87
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cervomed Inc
Cervomed Inc
Buy
$165.1M
114.1%
NA
-51.36%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Company Information

diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but

Organization
Cervomed Inc
Employees
8
CEO
Dr. John J. Alam M.D.
Industry
Miscellaneous

FAQs